NASDAQ · Drug Manufacturers - Specialty & Generic

Evotec SE (EVO) Stock

$2.01 -6.07% NASDAQ: EVO Healthcare

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health.

Valuation

MetricValue
Price$2.01
Market Cap$713.93M
P/E Ratio-3.26
P/B Ratio0.90
P/S Ratio0.84
EPS (TTM)$-0.28
52-Week High$4.42
52-Week Low$1.97
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-24.55%
ROA-11.82%
ROCE-8.50%
Gross Margin11.47%
Operating Margin-13.88%
Net Margin-26.02%
Debt/Equity0.55
Current Ratio1.68

Annual Financials (USD)

Metric20212022202320242025
Revenue$618.0M$751.0M$781.0M$797.0M$757.0M
Operating Profit$41.0M$21.0M$-48.0M$-143.0M$-135.0M
Net Profit$216.0M$-176.0M$-84.0M$-196.0M$-99.0M
EPS$0.65$-0.49$-0.23$-0.56$-0.28
Op Margin6.6%2.8%-6.1%-17.9%-17.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.2B$2.3B$2.3B$1.9B$1.8B
Total Liabilities$857.0M$1.1B$1.1B$960.0M$965.0M
Cash$699.0M$401.0M$511.0M$306.0M$418.0M
Borrowings$513.0M$507.0M$815.0M$444.0M$447.0M

Latest News

Berenberg Downgrades Evotec to Hold From Buy, Cuts Price Target to EUR3.60 From EUR9.40 MT Newswires · Jul 16, 2026 Evotec Shares Fall After TD Cowen Downgrade MT Newswires · Jul 15, 2026 TD Cowen Downgrades Evotec to Hold From Buy, Adjusts Price Target to $2 From $4 MT Newswires · Jul 15, 2026 Cell-Based Assay Services for Preclinical Use Only Global Market Report 2026 Released — Profiles Charles River, Labcorp, Eurofins and Evotec GlobeNewswire · Jul 15, 2026 Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... GuruFocus.com · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$122.0M$206.0M$36.0M$18.0M$-9.0M
Investing Cash Flow$-363.0M$-594.0M$-229.0M$-203.0M$90.0M
Financing Cash Flow$-21.0M$-5.0M$-13.0M$-9.0M$-23.0M
Net Cash Flow$277.0M$-284.0M$96.0M$-205.0M$148.0M
Free Cash Flow$3.0M$24.0M$-180.0M$-114.0M$-79.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA-16.29
FCF Yield-6.74%
Quick Ratio1.60
Interest Coverage-7.08
Return 1Y-48.17%
Return 3Y-85.12%
Return 5Y-90.34%

Ownership

Insiders Held0.01%
Institutions Held2.15%
Institutions Float Held2.15%
Institutional HolderSharesReport Date
Mubadala Investment Co PJSC4,597,7012026-03-31
DCF Advisers, LLC1,065,2742026-03-31
WCM Investment Management, LLC627,2602026-03-31
ABC Arbitrage SA509,0502026-03-31
Optiver Holding B.v.283,5762026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALVOAlvotech $3.16 +3.10% -10.76 $1.07B 0.00%
AZTA $29.88 +6.22% -15.22 $1.38B 0.00%
HROW $39.09 +0.83% 14.50 $1.46B 0.00%
NVCR $16.39 +4.46% -15.27 $1.91B 0.00%
PCRX $25.02 -2.19% 178.08 $984.16M 0.00%

About Evotec SE

Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.

Evotec SE is headquartered in DE.

Evotec SE (EVO) stock trades at $2.01 with a market capitalization of $713.93M. The stock is valued at a price-to-earnings (P/E) ratio of -3.26, price-to-book of 0.90, price-to-sales of 0.84. Over the past 52 weeks the stock has ranged between $1.97 and $4.42, and currently trades 54.5% below its 52-week high.

On profitability, Evotec SE generates a return on equity (ROE) of -24.55%, return on capital employed of -8.50%, an operating margin of -13.88%, a net profit margin of -26.02%.

Official website: www.evotec.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides